Chronic Myelogenous Leukemia in Chronic Phase
4 clinical trials · Condition
◉ Watch Chronic Myelogenous Leukemia in Chronic Phase
| Record | Firm | Date |
|---|---|---|
| CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib (NCT01227577) | Novartis Pharmaceuticals | 2010-11-01 |
| Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response (NCT01043874) | Novartis Pharmaceuticals | 2009-12-01 |
| Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase) (NCT00237120) | Novartis | 2002-11-01 |
Track Chronic Myelogenous Leukemia in Chronic Phase automatically
Every clearance here is in the API, with alerts when new ones post.